Galecto, Inc.

Boston, MA · Founded 2019 · Biotech · Public

Optimized therapeutic molecules for blood disorders

Claim this profile

Follows are private to you and power your alerts

Updated · damoratx.com

Sector
Biotech
Headquarters
Boston, MA
Founded
2019
Latest Form D
$285M, Nov 2025
Total capital
$428M
Federal grants
None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
Private capital raised
$428M
3 Form D · last Nov 2025
11 months since last filing
Federal contracts
None on recordNo federal contract awards found.
Granted patents
None on recordNo USPTO grants. Applications publish after 18 months.

Capital timeline

202020212022202320242025FEDERAL ↑EQUITY ↓Cumulative $428M2nd Form D$64.2M3rd Form D$285M
202020212022202320242025FEDERAL ↑EQUITY ↓Cumulative $428M2nd Form D$64.2M3rd Form D$285M

Latest events

  • Private capital raisedForm D · SEC · 3rd filing$285M
  • Private capital raisedForm D · SEC · 2nd filing$64.2M
  • Private capital raisedForm D · SEC · 1st filing$79.1M

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Founders and team

From SEC Form D filings
  • Amit Q. MunshiDirectorNamed in SEC Form D filings
  • Carl T. GoldfischerDirectorNamed in SEC Form D filings
  • Chandra Q. LeoDirectorNamed in SEC Form D filings
  • Chao Q. KhuongDirectorNamed in SEC Form D filings
  • Christopher T. CainDirectorNamed in SEC Form D filings
  • David Q. ShapiroDirectorNamed in SEC Form D filings
Show all 19 people
  • Erez Q. ChimovitsDirectorNamed in SEC Form D filings
  • Garrett T. WinslowExecutive OfficerNamed in SEC Form D filings
  • Hans SchambyeExecutive Officer, DirectorNamed in SEC Form D filings
  • Jakob Dynnes HansenExecutive OfficerNamed in SEC Form D filings
  • Jayson T. DallasDirectorNamed in SEC Form D filings
  • Jon FreveExecutive OfficerNamed in SEC Form D filings
  • Julianne T. BrunoDirectorNamed in SEC Form D filings
  • Karen WagnerDirectorNamed in SEC Form D filings
  • Lori T. FirmaniExecutive OfficerNamed in SEC Form D filings
  • Peter T. HarwinDirectorNamed in SEC Form D filings
  • Soren Q. LemoniusDirectorNamed in SEC Form D filings
  • Soren Q. MollerDirectorNamed in SEC Form D filings
  • Stephan Q. ChristgauDirectorNamed in SEC Form D filings

What it has protected

No granted patents are on record.

USPTO usually publishes applications 18 months after filing, so recent applications may not be visible yet. Patents assigned under a different entity name won’t match.

Checked: USPTO granted patents and published applications · Oct 23, 2026

  • Headlamp Inc.Similar federal contract value in Biotech · null in contracts
  • NEUMEDICINES, INC.Similar federal contract value in Biotech · null in contracts
  • Zura Bio LtdSimilar federal contract value in Biotech · null in contracts
  • Allogene TherapeuticsSimilar federal contract value in Biotech · null in contracts
  • RayzeBioSimilar federal contract value in Biotech · null in contracts
  • ImvaxSimilar federal contract value in Biotech · null in contracts

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .